Pediatrix Medical Group, Inc. (MD) Pediatrix Medical Group, Inc. delivers specialized medical services for newborns, expectant mothers, and pediatric patients across the United States and Puerto Rico. The company offers crucial neonatal care to critically ill or prematurely born infants within hospital units, staffed by expert neonatal subspecialists and advanced practice clinicians. For pregnant individuals and their developing babies, Pediatrix provides comprehensive maternal-fetal medicine services in both clinical and inpatient settings, involving specialists such as maternal-fetal medicine physicians, obstetricians, and genetic counselors. Furthermore, the group delivers pediatric cardiology services, addressing both congenital and acquired heart conditions in patients ranging from the fetal stage through adulthood, under the care of dedicated pediatric cardiologists. Beyond these core areas, Pediatrix extends its expertise to various other pediatric subspecialties, including those requiring intensivists, surgeons, and ophthalmologists, and supplies vital support to hospital departments like emergency rooms and labor and delivery units. Established in 1979 in Sunrise, Florida, and formerly known as MEDNAX, Inc. until its renaming in July 2022, the company managed a network of approximately 2,700 physicians as of February 2022.
Sector: Services-Hospitals
Industry: Medical - Care Facilities
Pediatrix Medical Group, Inc. NYSE:MD Healthcare · Medical - Care Facilities
CLOSED · Nov 3 $30.60 CLOSED · Nov 3 Prev close $30.71 Close $30.60 0.00% AH close $30.60 VOL 1.18M $ Vol $36.12M RVOL 1.60x
Mkt Cap $2.39B
VOL 1.18M sh
$ Vol $36.12M
RVOL 1.60×
Press Release ● Major ⚠ 4
Pediatrix Medical Group Reports Third Quarter Results
Pediatrix Medical Group reported Q3 2026 revenue of $501.4 million, up 1.7% year-over-year, with Adjusted EPS of $0.72 versus $0.67 in the prior-year quarter.
GAAP net income fell to $47.0 million ($0.59 per diluted share) from $71.7 million ($0.84) a year ago, largely because the prior-year quarter included a $20.9 million gain on divested businesses; Adjusted EBITDA declined to $85.5 million from $87.3 million on higher expenses at existing units.
The company spent $83.0 million on share buybacks in the quarter, cutting weighted average shares to 79.7 million from 85.6 million.
Pediatrix guided full-year 2026 Adjusted EBITDA to $290-300 million, and management cited volume and pricing ahead of expectations.
• 5d ago AI analysis › Press Release
Pediatrix Medical Group 2026 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 29, 2026
Pediatrix Medical Group (NYSE: MD) will host its third quarter 2026 investor conference call and webcast on Thursday, October 29, 2026 at 9:00 a.m. ET.
A detailed earnings press release will be issued the morning of October 29 before market open; no results were disclosed in this notice.
This is a scheduling announcement only and carries no new financial information.
• 14d ago AI analysis › Press Release
HB Wealth Expands Into Texas With Experienced Three-Advisor Team
businesswire.com • 1mo ago Press Release
New Survey Finds Preparedness Gap: Most Americans Rely on Smartphones for Severe Weather Alerts, Yet Nearly 1 in 3 Have No Backup Alerting Method
Midland released a national survey revealing that while 61% of Americans rely on smartphones for severe weather alerts, 29% lack a backup method for receiving warnings during power or cell outages.
The research highlights a significant preparedness gap, showing that 36% of households do not have an emergency plan and 29% have taken no preparedness action in the past year.
To encourage safety, Midland is offering 20% off select weather radios, including the WR120 and ER310 PRO models, throughout National Preparedness Month.
• 2mo ago AI analysis › Press Release ⚠ 2
Pediatrix Medical Group Reports Second Quarter Results
Pediatrix Medical Group reported Q2 revenue of $487.8 million, up 4.0% year-over-year, with GAAP EPS rising to $0.49 and Adjusted EPS reaching $0.63.
Adjusted EBITDA increased 4.3% to $76.4 million, driven by recent acquisitions and favorable payor mix, despite a 2.1% decline in same-unit patient volume.
The company reaffirmed its full-year 2026 Adjusted EBITDA guidance range of $280 million to $300 million and utilized $42.7 million for share repurchases during the quarter.
• 2mo ago AI analysis › Press Release
Pediatrix Medical Group Provides Second Quarter Update
Pediatrix confirmed its second quarter payor mix remained stable, countering recent reports of unfavorable shifts in utilization and reimbursement trends across the healthcare sector.
The company reaffirmed its previously issued full year 2026 outlook for Adjusted EBITDA, maintaining the range of $280 million to $300 million.
Full results for the quarter ended June 30, 2026 will be released before market open on August 4, followed by a conference call at 9:00 a.m. ET.
• 3mo ago AI analysis › Press Release
Maryland Public Television earns 20 regional Emmy® Awards
globenewswire.com • 4mo ago Press Release
Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology
Pediatrix Medical Group announced the publication of a large multicenter study in the Journal of Perinatology regarding probiotic use and necrotizing enterocolitis (NEC) in preterm infants.
The study, which analyzed data from over 10,000 infants in the Pediatrix Clinical Data Warehouse, found that NEC rates rose in hospitals that sharply reduced probiotic use following the FDA's 2023 warning actions.
The findings suggest abrupt discontinuation of probiotics may have had unintended harmful consequences, though the observational study did not identify specific effective strains or doses.
• 5mo ago AI analysis › Press Release ● Major ⚠ 2
Pediatrix Medical Group Reports First Quarter Results
Pediatrix Medical Group reported Q1 revenue of $476.2 million and Adjusted EPS of $0.44, exceeding internal expectations driven by top-line growth and same-unit revenue increases of 2.8%.
Adjusted EBITDA rose 18% year-over-year to $58.2 million, supported by recent acquisitions and improved reimbursements, though same-unit patient volume dipped slightly.
The company reaffirmed its full-year 2026 Adjusted EBITDA guidance range of $280 million to $300 million, ending the quarter with $205.8 million in cash after deploying capital for share repurchases and seasonal working capital needs.
• 5mo ago AI analysis › 
